Cargando…
Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model
BACKGROUND: Previously, we reported on the unexpected development of distant metastases in the subcutaneous rat pancreas CA20948 tumor model after 4.5 weeks of treatment with RAD001-only or in combination with [(177)Lu-DOTA(0),Tyr(3)]octreotate ((177)Lu-DOTATATE) (Cancer Res. 73:12-8, 2013). Moreove...
Autores principales: | Bison, Sander M, Pool, Stefan E, Koelewijn, Stuart J, van der Graaf, Linda M, Groen, Harald C, Melis, Marleen, de Jong, Marion |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4070081/ https://www.ncbi.nlm.nih.gov/pubmed/24995150 http://dx.doi.org/10.1186/s13550-014-0021-y |
Ejemplares similares
-
Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016) -
Bone marrow dosimetry in peptide receptor radionuclide therapy with [(177)Lu-DOTA(0),Tyr(3)]octreotate
por: Forrer, Flavio, et al.
Publicado: (2009) -
177Lu-DOTA-0-Tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT
por: Mazzara, Christophe, et al.
Publicado: (2022) -
Cellular dosimetry of [(177)Lu]Lu-DOTA-[Tyr(3)]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity
por: Tamborino, Giulia, et al.
Publicado: (2020) -
Subacute haematotoxicity after PRRT with (177)Lu-DOTA-octreotate: prognostic factors, incidence and course
por: Bergsma, Hendrik, et al.
Publicado: (2015)